News & Updates
Filter by Specialty:
Rezvilutamide-ADT trumps bicalutamide-ADT for high-volume mHSPC
In the interim analyses of the phase III CHART trial, a combination regimen of ADT* and the novel second-generation androgen-receptor (AR) inhibitor rezvilutamide trumped the bicalutamide-ADT combination in terms of survival outcomes in individuals with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).
Rezvilutamide-ADT trumps bicalutamide-ADT for high-volume mHSPC
14 Nov 2022
HKU programme offers free comprehensive genomic profiling tests to NSCLC patients
The University of Hong Kong (HKU) has launched a precision oncology programme in partnership with public and private stakeholders to provide free comprehensive genomic profiling tests to 1,800 eligible patients with stage IV non-small-cell lung cancer (NSCLC) in Hong Kong. Initial data from the programme revealed less common mutations amenable to treatment with targeted therapies in a sizeable proportion of patients.
HKU programme offers free comprehensive genomic profiling tests to NSCLC patients
14 Nov 2022
KEYNOTE-240 4.5-year follow-up supports pembrolizumab’s role in 2L advanced HCC treatment
An extended 4.5-year follow-up of the phase III KEYNOTE-240 trial showed that pembrolizumab continued to provide clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS), with a manageable safety profile, vs placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC).
KEYNOTE-240 4.5-year follow-up supports pembrolizumab’s role in 2L advanced HCC treatment
11 Nov 2022
Testosterone, prostate volume influence lower urinary tract symptoms in prostate cancer
Among prostate cancer patients on androgen deprivation therapy (ADT), a small prostate and higher reductions in testosterone levels appear to aggravate storage symptoms, a recent study has found.
Testosterone, prostate volume influence lower urinary tract symptoms in prostate cancer
10 Nov 2022
First-line pembrolizumab feasible for BRAF V600–mutant melanoma
A recent study recommends the use of pembrolizumab over BRAF/mitogen-activated protein kinase inhibitors, such as dabrafenib/trametinib, as first-line treatment in patients with advanced BRAF V600‒mutant advanced malignant melanoma.
First-line pembrolizumab feasible for BRAF V600–mutant melanoma
10 Nov 2022
Nursing interventions boost sexual QoL of breast cancer patients
Nursing interventions such as psychological and educational assistance help improve the sexual quality of life (QoL) among patients with breast cancer, reports a recent study.
